

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07731 A2

(51) International Patent Classification⁷: **A61K 31/557**,
31/5575, A61P 27/06

(21) International Application Number: PCT/JP01/06211

(22) International Filing Date: 18 July 2001 (18.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/620,416 20 July 2000 (20.07.2000) US
09/734,692 13 December 2000 (13.12.2000) US

(71) Applicant (*for all designated States except US*): SU-
CAMPO AG [CH/CH]; Graben 5, CH-6300 Zug (CH).

(72) Inventor: and

(75) Inventor/Applicant (*for US only*): **UENO, Ryuji** [JP/US];
11025 Stanmore Drive, Potomac, Montgomery, MD 20854
(US).

(74) Agents: **AOYAMA, Tamotsu** et al.; AOYAMA & PART-
NERS, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Os-
aka-shi, Osaka 540-0001 (JP).

(81) Designated States (*national*): AE, AG, AI, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITION FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

(57) Abstract: 15-keto prostaglandin compounds containing a ring structure at the end of the omega chain are used as ocular applied
intraocular pressure reducing agents. They are applied in a dose below the known dose for the corresponding 15-OH compound.

WO 02/07731 A2

at a dosage of one drop, or about 30 μ l, providing 1.5 μ g per dose. Latanoprost is named by Stjernschantz as 13, 14-dihydro-17-phenyl-18, 19,20-trinor-PGF₂ α isopropyl ester.

5 Another compound of this family known to date is 13,14-dihydro-15-oxo-17-phenyl- 18,19,20-trinor PGF₂ α isopropyl ester, hereinafter referred to as 15-keto latanoprost.

10 The above noted patent describes a wide potential dosage range as therapeutically active. For example, see column 5, lines 33-66 of the '128 patent ("The composition contains about 0.1-30 μ g, especially 1-10 μ g, per application of the active substance . . .") Even so, the lowest dosage used in the '128 patent for any test
15 compound for evaluating IOP reduction in humans or monkeys is 1.0 μ g per eye. For 15-keto latanoprost in the '128 patent, the tested dosage in healthy human volunteers is 5 μ g per eye and is 3 μ g in the monkey eye. Latanoprost is tested in the '128 patent at a dosage of 1.0 μ g per eye in
20 healthy human volunteers and at a dosage of 10.4 μ g in the monkey eye.

Latanoprost at its clinical concentration can cause pigmentation of the iris, a mild IOP spike and/or mild hyperemia.

25 SUMMARY OF THE INVENTION

effective dose of the corresponding 15-OH compound.

In another aspect, the present invention relates to an ophthalmic composition for maintaining a reduced intraocular pressure in a mammal by periodically
5 administering the same to the mammal, which comprises an effective amount of a 15-keto prostaglandin compound containing a ring structure at the end of the omega chain.

In another aspect, the present application also relates to use of a 15-keto prostaglandin compound containing a
10 ring structure at the end of the omega chain for manufacturing the above described ophthalmic composition.

DESCRIPTION OF THE DRAWING

Figures 1 and 2 set forth the results of Example 1 comparing the employment of a dose of 0.175 μ g
15 latanoprost (Fig. 1) and the same dose of 15-keto latanoprost (Fig 2) in the monkey eye.

Figure 1 shows effect of 0.0005% latanoprost on intraocular pressure (IOP) in monkeys. Latanoprost was instilled into the right eye. The left eye received the
20 vehicle. No significant difference between the latanoprost-treated eye and the vehicle treated contralateral eye (Student's t-test)

Figure 2 shows effect of 0.0005% 15-keto-latanoprost on intraocular pressure (IOP) in monkeys. 15-keto-
25 latanoprost was instilled into the right eye. The left eye


alone.

##p<0.01 as compared with 0.005% latanoprost + 0.0005% latanoprost (Turkey's comparison)

DETAILED DESCRIPTION OF THE INVENTION

5 The present invention relates to the employment of varying, including small, ocular dosages of a 15-keto prostaglandin compound containing a ring structure at the end of the omega chain as an IOP reducing agent, administered topically to the eye in the treatment of
10 glaucoma or ocular hypertension.

The preferred 15-keto prostaglandin compound of the present invention is represented by the formula (I),



15 wherein L and M are hydrogen atom, hydroxy, halogen atom, lower alkyl, lower alkoxy, hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

20 A is -CH₂OH, -COCH₂OH, -COOH or a functional derivative thereof;

B is -CH₂-CH₂-, -CH=CH- or -C≡C-;

The term "lower" throughout the specification is intended to include a group having 1 to 6 carbon atoms unless otherwise specified.

5 The term "lower alkyl" refers to a straight or branched chain saturated hydrocarbon group containing 1 to 6 carbon atoms and includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.

The term "lower alkoxy" refers to a group of lower alkyl-O-, wherein lower alkyl is as defined above.

10 The term "hydroxy(lower)alkyl" refers to a lower alkyl as defined above which is substituted with at least one hydroxy group such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 1-methyl-1-hydroxyethyl.

15 The term "lower alkanoyloxy" refers to a group represented by the formula RCO-O-, wherein RCO- is an acyl group formed by oxidation of a lower alkyl group as defined above, such as acetyl.

20 The term "cyclo(lower)alkyl" refers to a cyclic group formed by cyclization of a lower alkyl group as defined above but contains three or more carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

25 The term "cyclo(lower)alkyloxy" refers to the group of cyclo(lower)alkyl-O-, wherein cyclo(lower)alkyl is as defined above.

are as described above.

The term "heterocyclic-oxy group" means a group represented by the formula HcO- , wherein Hc is a heterocyclic group as described above.

5 The term "functional derivative" of A includes salts (preferably pharmaceutically acceptable salts), ethers, esters and amides.

Suitable "pharmaceutically acceptable salts" include conventionally used non-toxic salts, for example a salt with
10 an inorganic base such as an alkali metal salt (such as sodium salt and potassium salt), an alkaline earth metal salt (such as calcium salt and magnesium salt), an ammonium salt; or a salt with an organic base, for example, an amine salt (such as methylamine salt, dimethylamine
15 salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethylamino)ethane salt, monomethyl-monoethanolamine salt, procaine salt and
20 caffeine salt), a basic amino acid salt (such as arginine salt and lysine salt), tetraalkyl ammonium salt and the like. These salts may be prepared by a conventional process, for example from the corresponding acid and base or by salt interchange.

Examples of the ethers include alkyl ethers, for
25 example, lower alkyl ethers such as methyl ether, ethyl

phenyl ester, tosyl ester, t-butylphenyl ester, salicyl ester, 3,4-di-methoxyphenyl ester and benzamidophenyl ester; and aryl(lower)alkyl ester such as benzyl ester, trityl ester and benzhydryl ester.

5 The amides of A mean a group represented by the formula $-\text{CONR}'\text{R}''$, wherein each of R' and R'' is hydrogen atom, lower alkyl, aryl, alkyl- or aryl-sulfonyl, lower alkenyl and lower alkynyl, and include for example lower alkyl amides such as methylamide, ethylamide, dimethylamide
10 and diethylamide; arylamides such as anilide and toluidide; and alkyl- or aryl-sulfonylamides such as methylsulfonylamide, ethylsulfonyl-amide and tolylsulfonylamide.

 Preferred examples of L and M include hydroxy and
15 oxo, and especially, M and L are hydroxy to provide a 5-membered ring structure of, so called, PGF type.

 Preferred A is $-\text{COOH}$, $-\text{CH}_2\text{OH}$, or its pharmaceutically acceptable salt, ester, ether or amide thereof.

20 Preferred R_1 is an unsubstituted saturated or unsaturated bivalent lower-medium aliphatic hydrocarbon residue. It may preferably have 1-10 carbon atoms, more preferably, 2-8 carbon atoms.

 Examples of R_1 include, for example, the following

25 $-\text{CH}_2-\text{CH}_2-$,

having a primary type configuration and a compound of a non-primary type configuration.

When a 15-keto-PG compound of the present invention has for example a single bond between carbon atom number
5 13 and 14, the compound may be in the keto-hemiacetal equilibrium by formation of a hemiacetal between hydroxy at position 11 and oxo at position 15.

If such tautomeric isomers as above are present, the proportion of both tautomeric isomers varies with the
10 structure of the rest of the molecule or the kind of the substituent present. Sometimes one isomer may predominantly be present in comparison with the other. However, it is to be appreciated that the compounds used in the invention include both isomers. Further, while the
15 compounds used in the invention may be represented by a structure formula or name based on keto-type regardless of the presence or absence of the isomers, it is to be noted that such structure or name does not intend to exclude the hemiacetal type compound.

20 The present invention includes any of the isomers such as the individual tautomeric isomers, a mixture thereof, or the optical isomers, a mixture thereof, a racemic mixture, and other steric isomers useful for the same purpose.

In the method of the present invention, the above-
25 described compounds are topically administered to the

compound causes substantially no or less side effects including iridic pigmentation, an initial IOP spike and any hyperemia than those of the corresponding 15-OH compound. Accordingly, in the embodiment where the ophthalmic composition of the present invention is to be used for reducing IOP or for treating glaucoma in a mammal, the composition contains the 15-keto prostaglandin compound in an amount which provides a dose of the 15-keto prostaglandin compound below the therapeutically effective dose of the corresponding 15-OH compound.

As noted above, the clinical dose for latanoprost is about 1.5 μg per eye. At one-tenth the clinical dose, latanoprost is essentially inactive. Quite surprisingly, 15-keto latanoprost is an effective IOP reducing agent when used at about one-tenth the clinical dose of latanoprost. It is contemplated in one embodiment of the present invention that the dosage range for 15-keto latanoprost as a topically applied ocular IOP reducing agent is about 0.05 to 0.75 $\mu\text{g}/\text{eye}$, preferably about 0.075 to 0.25 $\mu\text{g}/\text{eye}$, more preferably about 0.1 to 0.175 $\mu\text{g}/\text{eye}$. In another embodiment of the present invention, the dosage range for 15-keto latanoprost as a topically applied ocular IOP reducing agent is about 0.05 to below 5.0 $\mu\text{g}/\text{eye}$, or about 0.1 to 4.5 $\mu\text{g}/\text{eye}$, or about 0.5 to 2.5 $\mu\text{g}/\text{eye}$, or about 1.0 to 2.0 $\mu\text{g}/\text{eye}$.

µg/eye, preferably about 0.075 to 0.25 µg/eye, more preferably about 0.1 to 0.175 µg/eye.

Another family of 15-keto prostaglandin compounds which should be useful in the practice of the present invention are 15-oxo-17-phenyl-18,19,20-trinor PGF₂α N-ethylamide and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF₂α N-ethylamide. The low dosage contemplated herein for these compounds is below 15 µg/eye to as low as 0.05 µg/eye. In another embodiment of this invention, these two compounds are topically applied to the eye in a dosage of about 10µg to 0.1 µg/eye, or about 8µg to 0.5µg/eye, or about 6µg to 1 µg/eye. See U.S. 5,352,708 and U.S. 6,037,364 for the corresponding 15-OH compound, 17-phenyl-18,19,20 trinor PGF₂α N-ethylamide, which has a clinical (daily) dose (FDA approved dose) of one drop of a 0.030% solution. As of this writing the clinical dosage of this compound is not known by the applicant; however, with typical drop sizes of about 20 to 50 µl, most usually about 30 to 35 µl, the dosage is estimated at about 6 to 15 µg/eye, probably about 9 µg/eye.

In the embodiment where the ophthalmic composition of the present invention is to be used for maintaining a reduced intraocular pressure in a mammal, the dose of the 15-keto compound is not limited. The dose of the 15-keto prostaglandin compound in this embodiment may be

The intraocular pressure lowering effects of the 0.0005% solution of 13,14-dihydro-15-keto-17-phenyl-18, 19,20-trinor-PGF₂α-isopropyl ester (15-keto-latanoprost) and the 0.0005% solution of 13,14-dihydro-17-phenyl-
5 18,19,20-trinor-PGF₂α-isopropyl ester (latanoprost) were compared following a single, topical ocular instillation in monkeys.

No intraocular pressure lowering effect was noted following the instillation of 0.0005% latanoprost. On the
10 other hand, the instillation of 0.0005% 15-keto-latanoprost lowered the intraocular pressure by 2.4 mmHg 8 hours after the administration as compared with the pre-treatment value. . The reduction in the intraocular pressure by the instillation of 15-keto-latanoprost was statistically
15 significant as compared with that by the instillation of the vehicle (contralateral eye) or of 0.0005% latanoprost.

These results indicate that 15-keto-latanoprost exerts a potent intraocular pressure lowering effect with a minute dose, and suggest that 13,14-dihydro-15-keto-17-phenyl-
20 18,19,20-trinor- PGF₂α (15-keto acid of latanoprost) itself produced as a metabolite from latanoprost in the eyes participates in the reduction in the intraocular pressure after the instillation of latanoprost.

Materials and Methods

1. Test substance

25

Group	Administration method	Volume of administration	n
15-keto-latanoprost 0.0005%	Instillation	35 μ L/eye	5
Latanoprost 0.0005%	Instillation	35 μ L/eye	5

Five monkeys were divided into 2 groups of the group 1 (3 monkeys) and group 2 (2 monkeys). The 0.0005% 15-keto-latanoprost and 0.0005% latanoprost were instilled into the right eye of monkeys in the group 1 and 2, respectively. One week later, 0.0005% latanoprost and 0.0005% 15-keto-latanoprost were instilled into the right eye of monkeys in the group 1 and 2, respectively, in a crossover way. Thirty-five μ L of each test solution was administered by use of a micropipet (Pipetman P 100, Gilson). To the left eye the same volume of the vehicle was administered. The intraocular pressure in each group before the instillation was as follows (in mmHg, mean \pm S.E.): the group receiving 15-keto-latanoprost; the right eye: 16.6 ± 0.5 , the left eye: 16.6 ± 0.2 , the group receiving latanoprost; the right eye: 15.8 ± 0.7 , the left eye: 17.0 ± 0.3 . There were no statistically significant differences between the values of the intraocular pressure before the instillation (Student's t-test).

5. Measurement of intraocular pressure

The animals were systemically anesthetized by an

keto-latanoprost was also statistically significant as compared with 0.0005% latanoprost.

Discussion

In the present study, the intraocular pressure lowering effects of latanoprost and 15-keto-latanoprost in monkeys were compared following a single instillation at 0.0005%, for about one-tenth the amount of clinically used latanoprost. While no reduction in the intraocular pressure was noted following the instillation of 0.0005% latanoprost, the instillation of 0.0005% 15-keto-latanoprost significantly lowered the intraocular pressure.

Above results clearly indicate that the potency of intraocular pressure lowering effect of 15-keto-latanoprost is significantly greater than that of latanoprost. Furthermore, the fact that 15-keto-latanoprost exerted a significant intraocular pressure lowering effect at such a low concentration, at which latanoprost had no effect, strongly suggests that 15-keto acid of latanoprost, a 13,14-dihydro-15-keto-type metabolite produced from latanoprost in the eyes, participates in the intraocular pressure lowering effect after the instillation of latanoprost.

References

- 1) Sjöquist B., et al.: Drug metabolism and disposition (8): 745-754, 1998

produced from latanoprost in the eye after instillation of latanoprost participates in the maintenance of the intraocular pressure lowering effect after instillation of latanoprost.

5 I. Introduction

In the present study, the animals were treated by the instillation with latanoprost at the clinical concentration alone, or additional instillation of a small amount of latanoprost or 15-keto-latanoprost 12 hours after instillation
10 of latanoprost when the IOP showed the maximum reduction after instillation of latanoprost. The changes of IOP in 3 different treatment groups were compared to investigate the significance of the presence of 15-keto acid of latanoprost, a 13,14-dihydro-15-keto type metabolite, in maintaining the
15 IOP lowering effect observed after instillation of latanoprost.

II. Materials and Methods

1. Test substance

15-keto-latanoprost and latanoprost which were synthesized in Ueno Institute for Medical Science were
20 used.

2. Animals

Six male cynomolgus monkeys (body weight: 3.2 - 3.8 kg) were used. These monkeys were housed individually in cages for monkeys in a monkey rearing room which was
25 maintained at room temperature of $24 \pm 1^{\circ}\text{C}$, relative

observed after instillation of latanoprost.

The following 3 treatments were given to the right eye of monkeys at the intervals of at least 10 days. Namely, (1) instillation of 0.005% latanoprost alone, (2) additional
5 instillation of 0.0005% latanoprost at 12 hours after instillation of 0.005% latanoprost, and (3) additional instillation of 0.0005% 15-keto-latanoprost at 12 hours after instillation of 0.005% latanoprost. Thirty μ L of each test
10 substance was instilled into the right eye of animals with a Pipetman (Gilson). The same amount of the vehicle was instilled into the left eye.

5. Measurement of IOP

After the ocular surface of monkeys was anesthetized with 0.4% oxybuprocaine hydrochloride (Benoxil® 0.4%
15 solution, Santen Pharmaceutical Co., Ltd.) under i.m. systemic anesthesia with 5 - 7.5 mg/kg of ketamine hydrochloride, IOP was measured with an applanation pneumatonograph (Alcon Japan Ltd.). IOP was measured before instillation and at 4, 8, 12, 16, 20, 24, 28 and 32
20 hours after instillation of 0.005% latanoprost.


III. Results

As Fig. 4 shows, when 0.005% latanoprost alone was instilled into the eye of monkeys, IOP decreased with time at 4, 8 and 12 hours after instillation. The IOP returned
25 with time toward the predosing levels at 16 and 20 hours

CLAIMS

1. An ophthalmic composition for reducing intraocular pressure or for treating glaucoma in a mammal, which comprises a 15-keto prostaglandin compound containing a ring structure at the end of the omega chain in a dose below the therapeutically effective dose of the corresponding 15-OH compound.

2. The composition of claim 1, wherein the 15-keto-prostaglandin compound is represented by the formula (I),




wherein L and M are hydrogen atom, hydroxy, halogen atom, lower alkyl, lower alkoxy, hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

A is -CH₂OH, -COCH₂OH, -COOH or a functional derivative thereof;

B is -CH₂-CH₂-, -CH=CH- or -C≡C-;

R₁ is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is

32



Wherein L and M are hydrogen atom, hydroxy, halogen atom, lower alkyl, lower alkoxy, hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

A is $-\text{CH}_2\text{OH}$, $-\text{COCH}_2\text{OH}$, $-\text{COOH}$ or a functional derivative thereof;

B is $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$;

R_1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, an alkyl group, hydroxy, oxo, aryl or heterocyclic group; and

Ra is a saturated or unsaturated lower aliphatic hydrocarbon residue, at the end of which is substituted with an aryl or aryloxy group.

9. The composition of claim 7, wherein the 15-keto prostaglandin compound is 13,14-dihydro-15-keto-18,19,20-trinor-PGF 2α isopropyl ester.

10. The composition of claim 7, wherein the mammal is a human.

Ra is a saturated or unsaturated lower aliphatic hydrocarbon residue, at the end of which is substituted with an aryl or aryloxy group.

13. The method of claim 11, wherein the 15-keto prostaglandin compound is 13,14-dihydro-15-keto-18,19,20-trinor-PGF2 α isopropyl ester.


14. The method of claim 11, wherein the dose is about one-tenth the therapeutically effective dose of the corresponding 15-OH compound.

15. The method of claim 13, wherein the dose is about 0.05 to below 5.0 μ g per eye.

16. The method of claim 11, wherein the mammal is a human.

17. A method for maintaining a reduced intraocular pressure in a mammal by periodically administering to the eyes of the mammal an effective amount of a 15-keto prostaglandin compound containing a ring structure at the end of the omega chain.


18. The method of claim 17, wherein the 15-keto prostaglandin compound is represented by the formula (I),



(I)

prostaglandin compound in a dose below the therapeutically effective dose of the corresponding 15-OH compound.

22. The use of claim 21, wherein the 15-keto-prostaglandin compound is represented by the formula (I),



wherein L and M are hydrogen atom, hydroxy, halogen atom, lower alkyl, lower alkoxy, hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

A is $-\text{CH}_2\text{OH}$, $-\text{COCH}_2\text{OH}$, $-\text{COOH}$ or a functional derivative thereof;

B is $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$;

R_1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, an alkyl group, hydroxy, oxo, aryl or heterocyclic group; and

Ra is a saturated or unsaturated lower aliphatic hydrocarbon residue, at the end of which is substituted with aryl, aryloxy.

23. The use of claim 21, wherein the 15-keto

hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

A is $-\text{CH}_2\text{OH}$, $-\text{COCH}_2\text{OH}$, $-\text{COOH}$ or a functional
5 derivative thereof;

B is $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-$ or $-\text{C}\equiv\text{C}-$;

R_1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, an alkyl group,
10 hydroxy, oxo, aryl or heterocyclic group; and

Ra is a saturated or unsaturated lower aliphatic hydrocarbon residue, at the end of which is substituted with an aryl or aryloxy group.

29. The use of claim 27, wherein the 15-keto
15 prostaglandin compound is 13,14-dihydro-15-keto-18,19,20-trinor-PGF 2α isopropyl ester.

30. The use of claim 27, wherein the mammal is a human.

2/2

Fig. 3





Fig. 4



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/007731 A3

(51) International Patent Classification⁷: **A61K 31/557**,
31/5575, A61P 27/06

(21) International Application Number: PCT/JP01/06211

(22) International Filing Date: 18 July 2001 (18.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/620,416 20 July 2000 (20.07.2000) US
09/734,692 13 December 2000 (13.12.2000) US

(71) Applicant (*for all designated States except US*): SU-
CAMPO AG [CH/CH]; Graben 5, CH-6300 Zug (CH).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): UENO, Ryuji [JP/US];
11025 Stanmore Drive, Potomac, Montgomery, MD 20854
(US).

(74) Agents: AOYAMA, Tamotsu et al.; AOYAMA & PART-
NERS, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Os-
aka-shi, Osaka 540-0001 (JP).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— with international search report

(88) Date of publication of the international search report:
3 April 2003

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITION CONTAINING A 15-KE τ O PROSTAGLANDIN COMPOUND FOR TREATING OF OCULAR HY-
PERTENSION AND GLAUCOMA

(57) Abstract: 15-keto prostaglandin compounds containing a ring structure at the end of the omega chain are used as ocular applied
intraocular pressure reducing agents. They are applied in a dose below the known dose for the corresponding 15-OH compound.

WO 02/007731 A3



C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 011 062 A (SCHNEIDER L WAYNE ET AL) 4 January 2000 (2000-01-04) abstract column 6, line 13 column 6, line 55 - line 65; claims ---	1-30
A	WO 99 51273 A (ALCON LAB INC) 14 October 1999 (1999-10-14) claims 1-5 ---	1-30
A	EP 0 366 279 A (UENO SEIYAKU OYO KENKYUJO KK) 2 May 1990 (1990-05-02) abstract; claims; examples ---	1-30
A	EP 0 308 135 A (UENO SEIYAKU OYO KENKYUJO KK) 22 March 1989 (1989-03-22) abstract; claims; examples -----	1-30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP 01/06211

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 11-20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 3,5,9,13,15,19,23,25,29
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 01/06211

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9951273	A		CA	2322579 A1	14-10-1999
			CN	1295483 T	16-05-2001
			EP	1069913 A1	24-01-2001
			JP	2002510654 T	09-04-2002
			NZ	506921 A	01-02-2002
			TR	200002848 T2	21-02-2001
			WO	9951273 A1	14-10-1999
			US	6261547 B1	17-07-2001
<hr/>					
EP 0366279	A	02-05-1990	JP	2008226 C	11-01-1996
			JP	2096528 A	09-04-1990
			JP	7039343 B	01-05-1995
			JP	2009965 C	02-02-1996
			JP	2096529 A	09-04-1990
			JP	7039344 B	01-05-1995
			AT	111736 T	15-10-1994
			AT	162074 T	15-01-1998
			DE	68918391 D1	27-10-1994
			DE	68918391 T2	19-01-1995
			DE	68928551 D1	19-02-1998
			DE	68928551 T2	23-04-1998
			EP	0366279 A2	02-05-1990
			EP	0580268 A2	26-01-1994
			US	6420422 B1	16-07-2002
			US	5194429 A	16-03-1993
			US	5236907 A	17-08-1993
<hr/>					
EP 0308135	A	22-03-1989	AT	72235 T	15-02-1992
			AT	82499 T	15-12-1992
			AT	108330 T	15-07-1994
			AU	600168 B2	02-08-1990
			AU	2231388 A	23-03-1989
			CA	1324129 A1	09-11-1993
			CA	1328075 A1	29-03-1994
			DE	3850676 D1	18-08-1994
			DE	3868127 D1	12-03-1992
			DE	3876050 D1	24-12-1992
			DE	3876050 T2	25-03-1993
			EP	0289349 A1	02-11-1988
			EP	0308135 A2	22-03-1989
			EP	0455264 A2	06-11-1991
			ES	2032016 T3	01-01-1993
			ES	2052735 T3	16-07-1994
			GB	2209939 A , B	01-06-1989
			GR	3003749 T3	16-03-1993
			GR	3006319 T3	21-06-1993
			JP	2592204 B2	19-03-1997
			JP	6080571 A	22-03-1994
			JP	1151552 A	14-06-1989
			JP	1941635 C	23-06-1995
			JP	6067900 B	31-08-1994
			JP	1858208 C	27-07-1994
			JP	2000108 A	05-01-1990
			JP	5071567 B	07-10-1993
			KR	9306202 B1	08-07-1993
			KR	9300051 B1	06-01-1993
			NZ	226197 A	25-02-1992
			US	5001153 A	19-03-1991